BioSpace News Archive

Business Activity Index at 64.7%; New Orders Index at 65.2%; Employment Index at 55.2%

Pfizer has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx’s Type 1 diabetes research program.

This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP101 in Huntington’s Disease and it further strengthen Mitochon’s exclusivity for MP-101, a repurposed molecule.

Loop Genomics deploys new sequencing technology and protocols to provide unparalleled insight into transcriptome research

Sage Therapeutics announced that, on March 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 12,550 shares of its common stock, and 4,025 performance restricted stock units to three new employees under Sage’s 2016 Inducement Equity Plan.

WeShareMD, a shared office concept designed specifically for medical professionals, has closed its seed round of funding.

Merck, known as MSD outside the United States and Canada, is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design.

Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott Copley Place in Boston.

Bristol-Myers Squibb Company will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston.